Hetero’s copy of COVID-19 drug Tocilizumab gets EUA from DCGI
The Hindu
A biosimilar version of Roche’s Actemra/RoActemra, product will be available by month end.
Drugmaker Hetero’s generic version of Tocilizumab has recieved Emergency Use Authorisation (EUA) from the Drugs Controller General of India (DCGI). A biosimilar version of Roche’s Actemra/RoActemra, the product (Tocilizumab 400mg/20ml) is to marketed under the Tocira brand name. It will be available by September end, Hetero said in a release on Monday. The EUA will enable medical practitioners to use the generic drug for treatment of COVID-19 in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), it said.More Related News